Biogen Idec Options Isis Pharmaceuticals’ Antisense Drug for Spinal Muscular Atrophy
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 1 (Table of Contents)
Published: 20 Jan-2012
DOI: 10.3833/pdr.v2012.i1.1672 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Biogen Idec has agreed to pay Isis Pharmaceuticals up to US$299 M to gain rights over ISIS-SMNRx, an antisense drug in Phase I development for spinal muscular atrophy (SMA)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS